Systematic evaluation of pharmacoeconomic studies on acute ischemic stroke population in China

WANG Lin; CHEN Zaiyu

doi:10.6039/j.issn.1001-0408.2023.05.12

您当前的位置：

首页 >

文章列表页 >

Systematic evaluation of pharmacoeconomic studies on acute ischemic stroke population in China

更新时间：2023-06-12

- Systematic evaluation of pharmacoeconomic studies on acute ischemic stroke population in China
- ZHONGGUO YAOFANG Vol. 34, Issue 5, Pages: 575-580(2023)
- 作者机构：
  
  中国药科大学国际医药商学院，南京　211198
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.05.12
  CLC： R956;R972
- Published：15 March 2023，
  
  Received：31 July 2022，
  
  Revised：03 February 2023，
扫描看全文
王琳,陈在余.中国急性缺血性卒中人群药物经济学研究的系统评价 ^Δ[J].中国药房,2023,34(05):575-580.

WANG Lin,CHEN Zaiyu.Systematic evaluation of pharmacoeconomic studies on acute ischemic stroke population in China[J].ZHONGGUO YAOFANG,2023,34(05):575-580.
王琳,陈在余.中国急性缺血性卒中人群药物经济学研究的系统评价 ^Δ[J].中国药房,2023,34(05):575-580. DOI： 10.6039/j.issn.1001-0408.2023.05.12.

WANG Lin,CHEN Zaiyu.Systematic evaluation of pharmacoeconomic studies on acute ischemic stroke population in China[J].ZHONGGUO YAOFANG,2023,34(05):575-580. DOI： 10.6039/j.issn.1001-0408.2023.05.12.

摘要

目的

对基于中国急性缺血性卒中（AIS）人群的药物经济学研究（模型法）进行系统评价，为完善AIS药物经济学评价方法提供建议。

方法

计算机检索中国知网、万方数据知识服务平台、维普网、PubMed、Embase、the Cochrane Library、ScienceDirect、Web of Science数据库，检索时限为2014年1月－2022年2月，搜集关于AIS药物经济学评价的相关文献，统计并分析纳入研究的基本信息、模型的基本信息以及结果指标。使用CHEERS 2022清单对纳入文献的质量进行评价，找出现有文献中存在的问题并提出建议。

结果

最终纳入12篇文献，包括中文5篇、英文7篇。所有研究均报告了研究角度，主要为卫生体系角度；目标人群的年龄主要分布在60岁左右；纳入研究中的主要干预措施为药物治疗，包括单一用药方案和联合用药方案；9篇文献采用决策树联合Markov模型，3篇文献单独使用Markov模型，但健康状态的划分方式不一致；所有文献均报告了研究时限和循环周期，大多数研究选择的研究时限为30年，循环周期为1年；所有研究均采用改良Rankin量表评分作为临床效果指标，该数据主要来源于临床试验；大多数文献中的效用值来源于已发表的研究，成本主要为直接医疗成本；所有研究均进行了成本-效用分析，以质量调整生命年和（或）增量成本-效果比作为结局指标，并进行了单因素敏感性分析和概率敏感性分析，但未针对可能存在的不同模型结构进行情境分析。

结论

纳入研究的总体报告内容较为完整，但方法学较为单一，在研究角度、研究时限、参数来源、情境分析等方面仍存在不足。今后的AIS药物经济学评价应按照CHEERS清单条目进一步完善报告内容，从全社会角度出发，对多种健康状态划分方式进行情境分析，同时采用真实世界来源的数据，并规范研究结果的不确定性分析过程，以增加研究结果的真实性与可靠性。

Abstract

OBJECTIVE

To systematically evaluate pharmacoeconomic studies （modeling approach） based on the Chinese acute ischemic stroke （AIS） population， and to provide the suggestions for improving the pharmacoeconomic evaluation method of AIS.

METHODS

Retrieved from CNKI， Wanfang Data Knowledge Service Platform， VIP， PubMed， Embase， the Cochrane Library， ScienceDirect， and Web of Science databases， relevant literature on pharmacoeconomic evaluation of AIS were collected from January 2014 to February 2022. Basic information of included study， basic information and outcome indicators of the model were analyzed statistically. The quality of the included literature was evaluated using CHEERS 2022， and problems in the existing literature were identified and suggestions were made.

RESULTS

Twelve papers were finally included， involving five in Chinese and seven in English. All studies reported the study perspective， mainly from the perspective of health system； the age of the target population was mainly distributed around 60 years old； the main interventions in the included studies were pharmacotherapy， including single-drug regimens and combination drug regimens； nine papers used decision trees combined with Markov models， and three papers used Markov models alone， but the classification of health status was inconsistent； all papers reported study time frame and cycle period， with most studies choosing a study time frame of 30 years and a cycle period of 1 year； all studies used modified Rankin scale scores as an indicator of clinical effectiveness， which were mainly derived from clinical trials； utility values in most literature were derived from published studies， and costs were mainly direct medical costs； all studies performed cost-utility analyses using quality-adjusted life years and/or incremental cost-effectiveness ratios as outcome indicators， and single-factor sensitivity analyses and probabilistic sensitivity analyses were performed， but no contextual analyses were conducted for the different model structures that may exist.

CONCLUSIONS

The overall report of the included studies is relatively complete， but the methodology is relatively uniform， and there are still deficiencies in terms of study perspective， study time frame， parameter sources， and contextual analysis. Future AIS pharmacoeconomic evaluations should further improve the report content in accordance with the CHEERS list entries， conduct contextual analysis of multiple health state classification approaches from a society-wide perspective， while using data from real-world sources and standardizing the uncertainty analysis process of the study results to increase the authenticity and reliability of the study results.

关键词

急性缺血性卒中药物经济学模型系统评价

Keywords

pharmacoeconomicsmodelsystematic evaluation

references

刘红玉，房伟. 缺血性脑卒中发病机制的研究进展[J]. 中国现代医生，2010，48（25）：11-12.

国家卫生健康委. 国家卫生健康委办公厅关于印发中国脑卒中防治指导规范（2021年版）的通知[EB/OL]. [2021-08-31]. http：//www.nhc.gov.cn/yzygj/s3593/202108/50c4071a86df4bfd9666e9ac2aaac605.shtmlhttp://www.nhc.gov.cn/yzygj/s3593/202108/50c4071a86df4bfd9666e9ac2aaac605.shtml.

国家统计局.2022中国卫生健康统计年鉴[EB/OL].[2022-09-03]. https：//www.yearbookchina.com/navibook- list-n3022110202-1.htmlhttps://www.yearbookchina.com/navibook-list-n3022110202-1.html.

左琨，杨新春，钟久昌. 急性缺血性脑卒中损伤机制及其治疗药物研究进展[J]. 药学进展，2019，43（8）：576-583.

HUSEREAU D，DRUMMOND M，AUGUSTOVSKI F，et al. Consolidated Health Economic Evaluation Repor- ting Standards 2022 （CHEERS 2022） statement：updated reporting guidance for health economic evaluations[J]. Value Health，2022，25（1）：3-9.

贾羽，刘建民，杨鹏飞，等. ReVive SE机械取栓对比静脉溶栓治疗中国急性缺血性卒中患者的成本效用分析[J]. 中国医疗保险，2019（4）：57-63.

潘岳松，王伊龙，廖晓凌，等. 急性缺血性卒中3 h内rt-PA溶栓的成本效用分析[J]. 中国卒中杂志，2016，11（6）：462-467.

王芳旭，陶立波，贾世欢，等. 缺血性脑卒中溶栓配合机械取栓对比单纯溶栓治疗的卫生经济学评价研究[J]. 中国医疗保险，2019（3）：58-64.

惠文，赵文博，居文慧，等. 血管再通策略治疗前循环大血管闭塞急性缺血性卒中的成本效果分析[J]. 中国脑血管病杂志，2020，17（3）：126-134，168.

王志恒，王晓梅，潘婕，等. 蛭蛇通络胶囊治疗中风（气虚血瘀证）的成本效用分析[J]. 中草药，2021，52（15）：4649-4657.

PAN Y S，CAI X L，HUO X C，et al. Cost-effectiveness of mechanical thrombectomy within 6 hours of acute ischae- mic stroke in China[J]. BMJ Open，2018，8（2）：e018951.

PAN Y，WANG Y L，LIU G，et al. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China[J]. Value Health，2014，17（7）：A725.

PAN Y S，ZHANG L，LI Z X，et al. Cost-effectiveness of a multifaceted quality improvement intervention for acute ischemic stroke in China[J]. Stroke，2020，51（4）：1265-1271.

XIANG Y L，YANG N，GUO Z T，et al. Cost-effectiveness analysis of ginkgolide injection in the treatment of ischemic stroke based on a randomized clinical trial[J]. J Altern Complement Med，2021，27（4）：331-341.

NI W Y，KUNZ W G，GOYAL M，et al. Quality of life and cost consequence of delays in endovascular treatment for acute ischemic stroke in China[J]. Health Econ Rev，2022，12（1）：4.

CAI Z L，CAI D，WANG R W，et al. Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack[J]. Sci Rep，2021，11（1）：7383.

PAN Y S，WANG A X，LIU G F，et al. Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke[J]. J Am Heart Assoc，2014，3（3）：e000912.

WANG Y L，PAN Y S，ZHAO X Q，et al. Recurrent stroke was associated with poor quality of life in patients with transient ischemic attack or minor stroke：finding from the CHANCE trial[J]. CNS Neurosci Ther，2014，20（12）：1029-1035.

PAN Y S，CHEN Q D，ZHAO X Q，et al. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China[J]. PLoS One，2014，9（10）：e110525.

GANESALINGAM J，PIZZO E，MORRIS S，et al. Cost-utility analysis of mechanical thrombectomy using stent retrievers in acute ischemic stroke[J]. Stroke，2015，46（9）：2591-2598.

CRESPO C，MORENO E，SIERRA J，et al. Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain[J]. Health Econ Rev，2013，3（1）：28.

刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国市场出版社，2020：16，72-73.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Study on the risk factors of cefoperazone/sulbactam-induced coagulation dysfunction in adult patients： a systematic review

Systematic review of the research on rational drug use among the elderly in Chinese elderly care facilities

中西医结合方案治疗脓毒症的Meta分析

他莫昔芬治疗多囊卵巢综合征疗效的系统评价

依那普利治疗原发性高血压的疗效与安全性的系统评价

Related Author

TUO Mingfu

TANG Cai’e

YANG Kun

SHEN Yabing

LEI Shixin

YANG Liang

WU Biao

WANG Jianhua

Related Institution

Dept. of Pharmacy， the Affiliated Hospital of Gansu Medical College

School of Basic Medical Sciences， Gansu Medical College

College of Pharmacy， Xinjiang Medical University

Dept. of Pharmacy， the First Affiliated Hospital of Xinjiang Medical University

State Key Laboratory of Pathogenesis， Prevention and Treatment of High Incidence Diseases in Central Asia， Xinjiang Medical University

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰